A team of researchers led by scientists at St. Jude Children’s Research Hospital is looking at ways to improve how blood-forming stem cells can be used for therapeutic interventions. The work has uncovered a group of genes that regulate how hematopoietic stem cells start to grow and thrive in mice. The function of many of these genes was previously unknown. Reconstitution of a robust blood-forming system is essential for recovery from many catastrophic diseases as well as from chemotherapy treatments. A report on this study appears today in the Journal of Experimental Medicine.
Hematopoietic stem cell transplantation is the only therapy that cures many catastrophic malignancies linked to bone marrow or immune system failure. However, generating sufficient quantities of viable stem cells for this type of intervention is immensely challenging. Despite efforts to increase the yield of blood-forming stem cells, the viability of these cells in culture remains a problem. As an alternative to this type of approach, St. Jude researchers are looking at ways to enhance how these rare but valuable stem cells take hold once transplanted into a new host.
“We recognized that one barrier to improving blood stem cell transplantation is a lack of understanding of how these blood-forming stem cells successfully grow in the challenged environment of transplant. So we set out to identify the genes that control this process,” said Shannon McKinney-Freeman, Ph.D., assistant member in the St. Jude Department of Hematology and the study’s corresponding author.
“Our hope is to decipher the critical molecular pathways that control the ability of these clinically valuable cells to transplant into a new host,” added Per Holmfeldt, formerly a postdoctoral fellow at St. Jude and one of the study’s authors.
According to the National Bone Marrow Registry, about 3,000 children require hematopoietic stem cell transplantation each year in the United States. Much of the mortality and morbidity linked to this type of transplantation is due to infection and other complications but could be addressed in some way by protocols that enhance the growth of new blood cells arising from transplanted stem cells.
After four years of work, a new screening method developed in mouse model systems turned up 17 genes that are novel regulators of hematopoietic stem cell transplantation. Thirteen of these genes had never before been linked to the biology of engraftment of blood-forming stem cells. Engraftment is when new blood-forming stem cells start to grow and produce healthy, mature blood cells.
The scientists were also able to pinpoint the role of the Foxa3 gene, which was shown for the first time to play an important role in repopulating blood-forming stem cells in the experimental system used by the researchers. Investigators found that Foxa3 likely regulates the blood-cell–forming response that takes place under the conditions of stress experienced after transplantation.
“Our functional screen in mice is a first step to enhancing hematopoietic stem cell transplantation. If we are to improve transplant outcomes in patients, we next need to study these identified genes and the molecules they specify in much more detail,” McKinney-Freeman said. “The more we understand the full scope of the molecular mechanisms that regulate stable engraftment of blood stem cells, the better equipped we will be to develop and clinically test novel therapies to improve health outcomes.”
The study’s other St. Jude authors are Miguel Ganuza, Himangi Marathe, Trent Hall, Guolian Kang, Joseph Moen and David Finkelstein. Additional authors are Bing He and Kai Tan, both of Children’s Hospital of Philadelphia; and Jennifer Pardieck, Angelica C. Saulsberry, Alba Cico, Ludovic Gaut, and Daniel McGoldrick.
This research was supported by funding from the American Society of Hematology, the National Institute of Diabetes and Digestive and Kidney Diseases (K01DK080846), the National Human Genome Research Institute (HG006130), BD, and ALSAC.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.